AUTHOR=Messina Nicole L. , Sperotto Mariana G. , Puga Marco A. M. , da Silva Patricia V. , de Oliveira Roberto D. , Moore Cecilia L. , Pittet Laure F. , Jamieson Tenaya , Dalcolmo Margareth , dos Santos Glauce , Jardim Bruno , Lacerda Marcus V. G. , Curtis Nigel , Croda Julio TITLE=Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination JOURNAL=Frontiers in Immunology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1172851 DOI=10.3389/fimmu.2023.1172851 ISSN=1664-3224 ABSTRACT=

Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.